Platelet-rich concentrates (PRCs), derived from a patient's blood, are being used in various fields of medicine, including dermatology, for an increasing number of indications. Although considered a generally safe procedure for dermatologic indications, there have been reports in the last several years linking this treatment to cases of blood-borne infections including HIV and hepatitis.1 Patient safety should always be the primary focus for physicians and other health care professionals, and systems-based protocols should exist within care settings to minimize errors. Herein, we review our protocol to decrease the risk of complications related to transmission of blood-borne infections and other medical errors related to PRCs. J Drugs Dermatol. 2024;23(9)790-791. doi:10.36849/JDD.8166.
Keyphrases
- patient safety
- healthcare
- quality improvement
- platelet rich plasma
- adverse drug
- randomized controlled trial
- palliative care
- hepatitis c virus
- hiv positive
- antiretroviral therapy
- emergency department
- case report
- hiv testing
- hiv aids
- pain management
- men who have sex with men
- social media
- combination therapy
- south africa